Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luke R Smart

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Blood Advances|April 9, 2026
Growth and puberty in African children with sickle cell anemia treated with hydroxyureaPhilippe Backeljauw, George Tomlinson, Luke R Smart, et al.
World Neurosurgery|June 1, 2017
Severe Traumatic Brain Injury at a Tertiary Referral Center in Tanzania: Epidemiology and Adherence to Brain Trauma Foundation GuidelinesLuke R Smart, Halinder S Mangat, Benson Issarow, et al.
American Journal of Hematology|February 9, 2024
Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trialAlexandra Power-Hays, George A Tomlinson, Leon Tshilolo, et al.
British Journal of Haematology|July 6, 2021
Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemiaCharles T Quinn, Omar Niss, Min Dong, et al.
Blood|November 14, 2022
Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan AfricaPeter Olupot-Olupot, George Tomlinson, Thomas N Williams, et al.
British Journal of Haematology|October 15, 2024
Baseline characteristics of Ghanaian children and adults enrolled in PIVOT, a randomised clinical trial of hydroxyurea in HbSC disease in sub-Saharan AfricaCatherine I Segbefia, Luke R Smart, Susan E Stuber, et al.
Acta Haematologica|August 17, 2022
Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan AfricaLuke R Smart, Emmanuela E Ambrose, Georgina Balyorugulu, et al.
Blood Advances|September 30, 2025
Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populationsAlexandra Power-Hays, Kathryn E McElhinney, Thomas N Williams, et al.
NEJM Evidence|December 8, 2024
Hydroxyurea for Children and Adults with Hemoglobin SC DiseaseYvonne A Dei-Adomakoh, Catherine I Segbefia, Teresa S Latham, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Blood Advances|April 9, 2026
Growth and puberty in African children with sickle cell anemia treated with hydroxyureaPhilippe Backeljauw, George Tomlinson, Luke R Smart, et al.
World Neurosurgery|June 1, 2017
Severe Traumatic Brain Injury at a Tertiary Referral Center in Tanzania: Epidemiology and Adherence to Brain Trauma Foundation GuidelinesLuke R Smart, Halinder S Mangat, Benson Issarow, et al.
American Journal of Hematology|February 9, 2024
Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trialAlexandra Power-Hays, George A Tomlinson, Leon Tshilolo, et al.
British Journal of Haematology|July 6, 2021
Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemiaCharles T Quinn, Omar Niss, Min Dong, et al.
Blood|November 14, 2022
Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan AfricaPeter Olupot-Olupot, George Tomlinson, Thomas N Williams, et al.
British Journal of Haematology|October 15, 2024
Baseline characteristics of Ghanaian children and adults enrolled in PIVOT, a randomised clinical trial of hydroxyurea in HbSC disease in sub-Saharan AfricaCatherine I Segbefia, Luke R Smart, Susan E Stuber, et al.
Acta Haematologica|August 17, 2022
Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan AfricaLuke R Smart, Emmanuela E Ambrose, Georgina Balyorugulu, et al.
Blood Advances|September 30, 2025
Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populationsAlexandra Power-Hays, Kathryn E McElhinney, Thomas N Williams, et al.
NEJM Evidence|December 8, 2024
Hydroxyurea for Children and Adults with Hemoglobin SC DiseaseYvonne A Dei-Adomakoh, Catherine I Segbefia, Teresa S Latham, et al.
Pageof 5